Innomedica OÜ
- Address
- lock Available on a paid plan
Rheumatology and Immune-Mediated Disease Research
At Innomedica OÜ in Tallinn, the clinical trial portfolio focuses on systemic lupus erythematosus and related immune system processes, with studies designed to better understand disease control and long-term treatment safety in adults with active autoimmune disease.
- Evaluating whether a new therapy can improve signs and symptoms of SLE compared with standard care or placebo
- Assessing the long-term safety of treatment for people living with moderately to severely active systemic lupus erythematosus
- Exploring how immune activity changes over time in autoimmune disease research
These studies help advance treatment options for complex inflammatory conditions and support better understanding of how to manage chronic rheumatologic disease.
Virus Diseases and Influenza Vaccine Research
The site also contributes to research in virus diseases, with a strong focus on influenza prevention in adults aged 50 years and older. This work examines whether different vaccine formulations produce consistent immune responses and adequate protection against seasonal influenza strains.
- Testing immune response consistency across multiple lots of an influenza vaccine
- Comparing antibody responses between vaccine formulations in older adults
- Supporting evaluation of vaccine effectiveness and immunogenicity in a higher-risk population
The research aims to strengthen confidence in influenza immunization by confirming that vaccines generate reliable immune protection in older adults and those with stable health conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Innomedica OÜ
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) | 3 | Unknown | 2023-11-03 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.